Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo  >  Shionogi & Co Ltd    4507   JP3347200002


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Shionogi & Co Ltd : Shionogi Provides Pirespa® 200mg Tablet to ILDONG PHARMACEUTICAL for the Treatment of Idiopathic Pulmonary Fibrosis in South Korea

share with twitter share with LinkedIn share with facebook
share via e-mail
10/12/2012 | 03:03am EDT
Shionogi Provides Pirespa® 200mg Tablet to ILDONG PHARMACEUTICAL for the Treatment of Idiopathic Pulmonary Fibrosis in South Korea

Osaka, Japan, October 12, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi" or "the Company") today announced that it began to supply Pirespa® 200mg tablet (generic name: pirfenidone) to ILDONG PHARMACEUTICAL Co., Ltd. (Head Office: Seoul; Chairman & CEO: Jung-chi Lee; hereafter "ILDONG") for the treatment of idiopathic pulmonary fibrosis (IPF) in South Korea from the end of September, 2012. Pirespa® is commercially available in South Korea through ILDONG since October 8, 2012.
Shionogi developed pirfenidone for the treatment of IPF in Japan after entered into the in-licensing agreement with the U.S.-based Marnac, Inc. and KDL, Inc., Tokyo in 1997. The Company received a marketing and manufacturing approval of pirfenidone for IPF in Japan in October and launched it as Pirespa® in December, 2008. It was the first time for the product to become available all over the world. Pirfenidone has a new mechanism of action which can directly inhibit fibrosis and the product is
expected to reduce the progression of IPF. The product has already been used for a lot of patients with
IPF as a new treatment option.
For the patients with IPF in South Korea, Shionogi and ILDONG entered into the licensing agreement for the sale of pirfenidone in May, 2011, and ILDONG had developed the product and received the approval after a fast track procedure as an orphan drug at the end of July, 2012. For the launch of Pirespa® by ILDONG in October, Shionogi began to provide the product to ILDONG at the end of September, 2012.
Shionogi will continue to support the treatment of patients with IPF by the stable supply of Pirespa® as well as by the provision of its accumulated clinical data in Japan, and to cooperate closely with ILDONG for the establishment of further clinical evidence of the product in Asia.

For Reference: About ILDONG PHARMACEUTICAL Co., Ltd.

Establishment: Representative: Head Office: Description of Business:
March 14, 1941
Chairman & CEO, Jung-chi Lee
60, Yangjae-dong, Seocho-gu, Seoul
ILDONG is a South Korean pharmaceutical company with the philosophy of "Excellence and Contribution to the Health and Happiness of Mankind", and which has worked to develop, produce and distribute superior
pharmaceutical products for 70 years. In particular, ILDONG is viewed as a


leading company in the production of vitamins, lactobacillus, antibiotics, and gastrointestinal preparations.

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is a medical condition of unknown etiology with poor prognosis in which progressive fibrosis of the alveolar walls produces irreversible "honeycomb lung*". In general, restrictive impairment (reduction of vital capacity (VC) and total lung capacity (TLC)) is evident. As the symptom (fibrosis of the alveolar walls) progresses, gas exchange in the lungs (exchange of oxygen and carbon dioxide) becomes difficult. In some cases, oxygen therapy becomes necessary. Because of
its severity, IPF is designated as a "specified disease" (in other words, an intractable disorder).

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIONOGI & CO LTD
09/09SHIONOGI : to Announce Personnel Reassignment
09/06SHIONOGI : to Announce Personnel Reassignment
09/02SHIONOGI : The Results of Analyses of PA/I38X-substituted Viruses in XOFLUZA® Cl..
09/02SHIONOGI : Positive Results for XOFLUZATM Global Phase III Study (MINISTONE-2) i..
09/02SHIONOGI : Announces Positive Post-Exposure Prophylaxis Results for XOFLUZA® in ..
09/02SHIONOGI : Special Drug Use Survey for XOFLUZA® Announced at OPTIONS X - Analysi..
08/30SHIONOGI : Announces XOFLUZA Tablets 20mg for The Treatment of Influenza Types A..
08/28SHIONOGI : Announces XOFLUZA® Tablets 20mg for The Treatment of Influenza Types ..
08/28SHIONOGI : to Participate in the United Nations Global Compact
08/22GSK's long acting HIV injection gets boost from study
More news
Financials (JPY)
Sales 2020 360 B
EBIT 2020 143 B
Net income 2020 128 B
Finance 2020 429 B
Yield 2020 1,71%
P/E ratio 2020 14,1x
P/E ratio 2021 13,6x
EV / Sales2020 3,87x
EV / Sales2021 3,51x
Capitalization 1 821 B
Duration : Period :
Shionogi & Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIONOGI & CO LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 7 175,45  JPY
Last Close Price 5 850,00  JPY
Spread / Highest target 50,4%
Spread / Average Target 22,7%
Spread / Lowest Target 9,40%
EPS Revisions
Isao Teshirogi President & Representative Director
Motozo Shiono Chairman
Kohji Hanasaki Manager-Accounting & Finance
Akio Nomura Independent Director
Teppei Mogi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIONOGI & CO LTD-5.26%16 859
JOHNSON & JOHNSON1.05%343 382
ROCHE HOLDING LTD.14.65%243 639
PFIZER-16.36%201 939
NOVARTIS15.63%198 194